CN114466868A - 一种双特异性融合蛋白及其应用 - Google Patents

一种双特异性融合蛋白及其应用 Download PDF

Info

Publication number
CN114466868A
CN114466868A CN202180005265.9A CN202180005265A CN114466868A CN 114466868 A CN114466868 A CN 114466868A CN 202180005265 A CN202180005265 A CN 202180005265A CN 114466868 A CN114466868 A CN 114466868A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
fusion protein
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180005265.9A
Other languages
English (en)
Inventor
房健民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rongchang Biopharmaceutical Yantai Co ltd
Original Assignee
Rongchang Biopharmaceutical Yantai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rongchang Biopharmaceutical Yantai Co ltd filed Critical Rongchang Biopharmaceutical Yantai Co ltd
Publication of CN114466868A publication Critical patent/CN114466868A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

提供了一种新型结构的双特异性融合蛋白,其在全长的IgG铰链区通过可选的肽接头插入第二结合结构域。该融合蛋白具备与IgG相同的表达和生产优势,不影响融合蛋白Fab区的结合活性并进一步提升了稳定性以及获得了更高的半衰期。另外第二结合结构域与靶向结合位点的结合活性相对于其对应可溶性天然结合片段的单体与相应靶点的结合活性相比,有了显著的提高。

Description

PCT国内申请，说明书已公开。

Claims (45)

  1. PCT国内申请，权利要求书已公开。
CN202180005265.9A 2020-03-20 2021-03-19 一种双特异性融合蛋白及其应用 Pending CN114466868A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010199036 2020-03-20
CN2020101990362 2020-03-20
PCT/CN2021/081659 WO2021185337A1 (zh) 2020-03-20 2021-03-19 一种双特异性融合蛋白及其应用

Publications (1)

Publication Number Publication Date
CN114466868A true CN114466868A (zh) 2022-05-10

Family

ID=77769172

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180005265.9A Pending CN114466868A (zh) 2020-03-20 2021-03-19 一种双特异性融合蛋白及其应用

Country Status (9)

Country Link
US (1) US20220204626A1 (zh)
EP (1) EP4056596A4 (zh)
JP (1) JP7489468B2 (zh)
KR (1) KR20220107257A (zh)
CN (1) CN114466868A (zh)
AU (1) AU2021237513B2 (zh)
CA (1) CA3137211A1 (zh)
TW (1) TW202136315A (zh)
WO (1) WO2021185337A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117986367A (zh) * 2024-04-02 2024-05-07 上海美迪西生物医药股份有限公司 靶点为Nectin-4的抗体及其应用
WO2024114605A1 (zh) * 2022-11-29 2024-06-06 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114467C (en) * 2019-08-29 2024-06-11 Remegen Co., Ltd. Anti pd-l1 antibody and use thereof
CN118159568A (zh) * 2021-10-21 2024-06-07 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
WO2024028386A1 (en) * 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103488A (zh) * 2014-02-10 2016-11-09 默克专利有限公司 靶向TGFβ抑制
US20170198050A1 (en) * 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017193032A2 (en) * 2016-05-06 2017-11-09 Medimmune, Llc Bispecific binding proteins and uses thereof
CN109721657A (zh) * 2017-10-27 2019-05-07 北京比洋生物技术有限公司 阻断pd-1／pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
US20200002417A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc Antitumor immune checkpoint regulator antagonists
US20200048351A1 (en) * 2018-07-09 2020-02-13 Intrexon Corporation Fusion constructs and methods of using thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347521A1 (en) * 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103488A (zh) * 2014-02-10 2016-11-09 默克专利有限公司 靶向TGFβ抑制
US20170198050A1 (en) * 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017193032A2 (en) * 2016-05-06 2017-11-09 Medimmune, Llc Bispecific binding proteins and uses thereof
CN109721657A (zh) * 2017-10-27 2019-05-07 北京比洋生物技术有限公司 阻断pd-1／pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
US20200002417A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc Antitumor immune checkpoint regulator antagonists
US20200048351A1 (en) * 2018-07-09 2020-02-13 Intrexon Corporation Fusion constructs and methods of using thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BINYAM BEZABEH ET AL: "Insertion of scFv into the hinge domain of full length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties", 《MABS》, vol. 9, no. 2, XP055465779, DOI: 10.1080/19420862.2016.1270492 *
JUANJUAN DU ET AL: "Engineering bisfunctional antibodies with constant region fusion architectures", 《JACS》, vol. 139, no. 51, XP055958145, DOI: 10.1021/jacs.7b09641 *
MANIKWAR PRAKASH ET AL: "Characterization of a novel bispecific antibody with improved conformational and chemical stability", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 109, no. 1, XP055794177, DOI: 10.1016/j.xphs.2019.06.025 *
刘伯宁: "靶向PD-L1与CD47双功能融合蛋白的制备与抑瘤活性研究", 《中国博士学位论文全文数据库医药卫生科技辑》, no. 06, pages 072 - 10 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114605A1 (zh) * 2022-11-29 2024-06-06 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
CN117986367A (zh) * 2024-04-02 2024-05-07 上海美迪西生物医药股份有限公司 靶点为Nectin-4的抗体及其应用

Also Published As

Publication number Publication date
CA3137211A1 (en) 2021-09-23
EP4056596A1 (en) 2022-09-14
US20220204626A1 (en) 2022-06-30
AU2021237513B2 (en) 2024-08-15
WO2021185337A1 (zh) 2021-09-23
KR20220107257A (ko) 2022-08-02
JP7489468B2 (ja) 2024-05-23
AU2021237513A1 (en) 2021-11-11
JP2023509005A (ja) 2023-03-06
EP4056596A4 (en) 2023-01-25
TW202136315A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
US11524991B2 (en) PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
Strohl Current progress in innovative engineered antibodies
JP7489468B2 (ja) 二重特異性融合タンパク質及びその応用
CN107903324B (zh) 一种结合人cd19和cd3的双特异性抗体
TW201803899A (zh) 三特異性和／或三價結合蛋白
US20200024358A1 (en) Trispecific antigen binding proteins
US11932675B2 (en) PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
JP2021520829A (ja) ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
JP2021521779A (ja) ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ−３抗原結合ドメインを含む、ＬＡＧ−３を標的とするヘテロ二量体融合タンパク質
CN111378044B (zh) 抗体融合蛋白、制备方法及其应用
CN109843928B (zh) 抗O-乙酰化的GD2神经节苷脂（OAcGD2）的人源化抗体
TWI815306B (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
WO2022026939A2 (en) Single and dual targeting ligand induced t-cell engager compositions
WO2020135804A1 (zh) 异源二聚体融合蛋白
WO2023045977A1 (zh) 白介素2突变体以及其融合蛋白
CN114127112A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
CN115667316A (zh) Fab-HCAb结构的结合蛋白
CN116874606B (zh) 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用
CN114773485B (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
WO2023011650A1 (zh) 一种多特异性抗体及其用途
WO2024121414A1 (en) Chimeric antigen receptor
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
CN115181180A (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其应用
CN118480129A (zh) 抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination